Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ZYME
Stock Latest News
The Fly
Zymeworks data for ZW191 ‘highly encouraging,’ says H.C. Wainwright
2d ago
ZYME
Premium
The Fly
Zymeworks assumed with an Equal Weigh at Wells Fargo
2d ago
ZYME
Premium
Ratings
Promising Early-Stage Data and Strategic Initiatives Drive Buy Rating for Zymeworks’ ZW191 Program
2d ago
ZYME
Premium
Ratings
Buy Rating for Zymeworks’ ZW191 Driven by Promising Efficacy and Favorable Safety Profile
3d ago
ZYME
Premium
Company Announcements
Zymeworks Reports Promising Phase 1 Results for ZW191 in Cancer Treatment
3d ago
ZYME
Premium
The Fly
Zymeworks reports preliminary results from Phase 1 study of ZW191
3d ago
ZYME
Premium
Ratings
Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform
6d ago
ZYME
Premium
Company Announcements
Zymeworks to Announce Q3 2025 Financial Results and Host Conference Call
10d ago
ZYME
Premium
Ratings
Zymeworks: Buy Rating Backed by Promising Pipeline and Strategic Partnerships
10d ago
ZYME
Premium
The Fly
JPMorgan ups Zymeworks target, places on ‘Positive Catalyst Watch’
10d ago
ZYME
Premium
Ratings
Zymeworks’ Promising Pipeline and Financial Projections Lead to Buy Rating
12d ago
ZYME
Premium
The Fly
Zymeworks upgraded to Buy from Neutral at H.C. Wainwright
12d ago
ZYME
Premium
Company Announcements
Zymeworks Presents Promising Phase 1 Data for ZW191 at International Conference
13d ago
ZYME
Premium
The Fly
Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
16d ago
ABT
MOS
Premium
The Fly
Zymeworks initiated with a Buy at B. Riley
16d ago
ZYME
Premium
Company Announcements
Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements
17d ago
ZYME
Premium
The Fly
Zymeworks appoints Adam Schayowitz as Acting Chief Development Officer
17d ago
ZYME
Premium
Ratings
Zymeworks’ Zanidatamab Shows Promising Potential in HERIZON-GEA-01 Trial with Significant Stock Upside
20d ago
ZYME
Premium
Ratings
Strategic Shift to Zanidatamab Drives Optimistic Buy Rating for Zymeworks
2M ago
ZYME
Premium
Ratings
Strategic Focus and Promising Pipeline Drive Buy Rating for Zymeworks
2M ago
ZYME
Premium
Company Announcements
Zymeworks Discontinues ZW171 Development Amidst Strategic Pipeline Focus
2M ago
ZYME
Premium
The Fly
Zymeworks to discontinue clinical development of ZW171
2M ago
ZYME
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
